Diabetes mellitus und Herz

Katharina Schütt; Dirk Müller-Wieland; Nikolaus Marx

doi:10.1055/a-0898-9937

Diabetologie und Stoffwechsel, Inhaltsverzeichnis

Diabetologie und Stoffwechsel 2019; 14(S 02): S232-S234
DOI: 10.1055/a-0898-9937

DDG-Praxisempfehlung

Diabetes mellitus und Herz

Katharina Schütt

Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen

,

Dirk Müller-Wieland

Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen

,

Nikolaus Marx

Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen

Literatur
1 Di Angelantonio E, Kaptoge S. Emerging Risk Factors C. et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA 2015; 314: 52-60 . doi:10.1001/jama.2015.7008
2 Consentino FF, Grant PJ, Aboyans V. et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019;
3 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine 2015; 373
4 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;
5 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2018; 380: 347-357
6 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322 . doi:10.1056/NEJMoa1603827
7 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;
8 Nichols GA, Gullion CM, Koro CE. et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884
9 MacDonald MR, Petrie MC, Varyani F. et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385
10 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975 . doi:10.1002/ejhf.592
11 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J 2016;